Blog

Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Photo taken from thelancet.com

Jan 21, 2024, 07:38

Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Amalya Sargsyan, Medical Oncologist at the

“Narek Shaverdian, among other experts, shared new promising data from phase II study on the role of body radiation therapy (SBRT) addition to standard of care (SOC) for Non-small cell lung cancer (NSCLC) and Breast c-r oligoprogression.

SBRT shows promise as an addition to SOC in NSCLC, offering a fourfold increase in PFS. SBRT plus SOC group showed Progression-free survival (PFS) of 10.0 months versus 2.2 months in SOC-only group (HR 0.41, 95%CI 0.22-0.75; p=0.0039)
No significant PFS difference with SBRT plus SOC for breast cancer.

Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC? Make sure to read the full article for more details.”

Source: Amalya Sargsyan/LinkedIn

Amalya Sargsyan cancer Narek Shahverdian Non-small-cell lung cancer (NSCLC) OncoDaily Oncology Stereotactic body radiation therapy (SBRT) Yeolyan Hematology and Oncology Center

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage